68 pharmaceutical executives leave, how do pharmaceutical stoices choose?

Guide: The Reason Behind The Frequent Departures of Executives?, about 68 of the listed pharmaceutical companies with revenues of more than $100 million in 2019 have adjusted their executive slevelof which Fosun Pharmaceuticals, Northeast Pharmaceuticals, Jiuzhitang, Dongcheng Pharmaceuticals, Jiangsu Wuzhong, Lisheng Pharmaceuticals 6 pharmaceutical companies have left the number of senior executives are 4 or more;(The first half of 2020 68 listed pharmaceutical companies executive departure statistics form, source: China Net Finance)the reasons behind the frequent departures of senior executives
in the above-mentioned statistics table on executive departures, "personal reasons" accounted for more than half of the public reasons for departure, in addition to "work adjustment", "family reasons" and so onof course, there are personal reasons for any departure, but the deep-seated reason behind it is worth thinking aboutIn 2020, in particular, the outbreak has hit the country and the global economy hardThe large-scale departures during this period are a bit of an anomalyWhat is the reason why so many pharmaceutical executives chose to leave at this particular time in the first half of this year?the reason is not complicated! Since the first half of this year, many pharmaceutical companies have been significantly affected by the epidemic, offline activities are limited, sales performance has been affected to varying degrees, which makes pharmaceutical companies have to start to adjust business patterns or direct changes in organizational structureIn this way, there will be a large or small influence between stakeholders within the companyThis has also led many executives to abandon their existing positions and choose to find another way"good gathering and dispersal" has always been China's way of etiquette, "decent leave than defeated stay more dignified."and in addition to sudden factors, in the long run, with the 4-7 band procurement, two-vote system, tender price reduction, medical insurance control fees and consistency evaluation and other national new round of medical reform policy, the pharmaceutical industry long-term pressure, pharmaceutical companies need to constantly adjust the business to adapt to the pharmaceutical market environment, which, regardless of pharmaceutical companies or senior management staff will look for more suitable talent and opportunitiesleave the wave, how do medical perpeople choose?'s career development is more intense in today's medical environment than the wave of executive departuresFor executives, whether forced to leave or take the initiative to leave, it may be more of a different stage, career development is not much impactBut for the under-the-ground medical staff, the departure of executives is like a "bomb", sparking panic and unease in the industryMany pharmaceutical workers worry about future jobs because of the departureof executives or because of their departuresthe retention of executives, especially straight-line executives, does have an impact on pharmaceutical sourm, but the impact is limited to short-term, specific jobsIn the broader direction and in the long run, the impact is minimalYou know, as long as your work content is still the same, your professional ability has not changed, the executive's stay will have any impact?in fact, medicine people can be based on this industry, only strengthAs we often hear, "Only when the tide recedes will we know who is swimming naked." "At any time, you can play your worth on any stage, and always be much smaller in the face of risk."so, no matter how the environment changes, the only thing medical people can do is to enhance their strength, through continuous learning to improve their business abilityThis way, even if forced to leave, by virtue of their ability to find a suitable job